Abstract Details

Title Disease Burden and Healthcare Utilization Among Patients with Acute Intermittent Porphyria Experiencing Chronic Neuropathy: Analyses from a National Healthcare Database

Topic General Neurology

Presentation(s) General Neurology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 051

Objective This study aimed to identify AIP patients diagnosed in a nationally representative health care database to estimate healthcare resource utilization among various segments of the AIP patients defined by porphyria attack rates, chronic symptoms, and comorbidities.

Background

Acute hepatic porphyria (AHP) refers to a family of rare, metabolic diseases that includes four types, acute intermittent porphyria (AIP) being the most common. AHP is characterized by potentially life-threatening acute attacks and, for some patients, chronic debilitating symptoms.

Design/Methods This retrospective analysis utilized the IBM^® MarketScan^® Commercial Claims and Medicare Supplemental Databases. Patients with at least one claim for AIP (ICD-10 diagnosis code E80.21) between October 1, 2015–June 30, 2018 were selected for analyses. AIP patients were segmented by frequency of attacks, presence of chronic symptoms and the presence of comorbidities. This analysis focused on the patient segment specific to chronic neuropathy. Means were reported as per patient per year (PPPY).

Results 56 (24.9%) patients with chronic neuropathy were identified; 80.4% female, mean (SD) age 49.9 years (14.8). Mean observation time of identified diagnosed patients was 2.0 years. Patients had a mean (SD) of 2.7 (3.4) attacks PPPY; 30.4% had ≥3 attacks/year. The majority had ≥1 hospitalization (57.1%) and emergency department (ED) visit (75.0%), with a mean (SD) of 1.0 (1.4) admissions and 7.5 (23.2) ED visits PPPY.

Conclusions Results from this national representative healthcare claims database demonstrated AIP patients experiencing chronic neuropathy have high disease burden and healthcare utilization.

Authors/Disclosures
Angelika Erwin PRESENTER	Angelika Erwin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alnylam. Angelika Erwin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Angelika Erwin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Angelika Erwin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Angelika Erwin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Angelika Erwin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Angelika Erwin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Angelika Erwin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
John Ko, PharmD, MS (Alnylam)	Dr. Ko has received personal compensation for serving as an employee of Alnylam Pharmaceuticals. Dr. Ko has received personal compensation for serving as an employee of Novartis. Dr. Ko has received stock or an ownership interest from Alnylam Pharmaceuticals. Dr. Ko has received stock or an ownership interest from Novartis.

��ɫ��

��ɫ��